TY - JOUR
T1 - Benefit and danger from immunotherapy in myasthenia gravis
AU - Rodolico, Carmelo
AU - Nicocia, Giulia
AU - Damato, Valentina
AU - Antonini, Giovanni
AU - Liguori, Rocco
AU - Evoli Stampanoni-B, Amelia
PY - 2021
Y1 - 2021
N2 - In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
AB - In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
KW - Checkpoint inhibitors
KW - Emerging therapy
KW - Immunotherapy
KW - Refractory myasthenia gravis
KW - Checkpoint inhibitors
KW - Emerging therapy
KW - Immunotherapy
KW - Refractory myasthenia gravis
UR - http://hdl.handle.net/10807/176470
U2 - 10.1007/s10072-021-05077-6
DO - 10.1007/s10072-021-05077-6
M3 - Article
SN - 1590-1874
VL - 42
SP - 1367
EP - 1375
JO - Neurological Sciences
JF - Neurological Sciences
ER -